Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs Johnson & Johnson — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.74, while Johnson & Johnson trades at $260.57 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | JNJ | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $267.24 |
52-Week Low | $16.74 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.69, up 2.25% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios, limiting fundamental analysis. Recent news highlights institutional interest in crypto ETFs, though BITQ itself is a US stock with no direct crypto operations.
The outlook remains cautious due to weak technicals and absent fundamentals. Risks include market volatility and unverified financial health. Analyst consensus is unavailable, requiring deeper research into company filings for investment clarity.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
